The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value

Abstract : The recently described oncogene ZNF217 belongs to a chromosomal region that is frequently amplified in human cancers. Recent findings have revealed that alternative mechanisms such as epigenetic regulation also govern the expression of the encoded ZNF217 protein. Newly discovered molecular functions of ZNF217 indicate that it orchestrates complex intracellular circuits as a new key regulator of tumorigenesis. In this review, we focus on recent research on ZNF217-driven molecular functions in human cancers, revisiting major hallmarks of cancer and highlighting the downstream molecular targets and signaling pathways of ZNF217. We also discuss the exciting translational medicine investigating ZNF217 expression levels as a new powerful biomarker, and ZNF217 as a candidate target for future anti-cancer therapies.
Type de document :
Article dans une revue
Oncotarget, Impact journals, 2015, 6 (39), pp.41566-81. 〈10.18632/oncotarget.5893〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-01427161
Contributeur : Hubert Lincet <>
Soumis le : jeudi 5 janvier 2017 - 12:57:50
Dernière modification le : mardi 19 juin 2018 - 01:18:15
Document(s) archivé(s) le : jeudi 6 avril 2017 - 13:22:01

Fichier

The dark side ZNF Oncotarget 2...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

Citation

Pascale Cohen, Caterina Donini, Nhan Nguyen, Hubert Lincet, Julie Vendrell. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value. Oncotarget, Impact journals, 2015, 6 (39), pp.41566-81. 〈10.18632/oncotarget.5893〉. 〈inserm-01427161〉

Partager

Métriques

Consultations de la notice

58

Téléchargements de fichiers

133